19
1
49
2
8
1b
1d
18
3e
45
1d
2 29
1d
25
Brian J. Czerniecki, M.D., Ph.D.
78
45
Emeritus Professor CE of Surgery
7
5e
Department: Surgery
4
1
b
1d
46
Contact information
43
4
3
3
3
2
4
b
1f
43
Department of Surgery
25 Division of Surgical Oncology
32 Hospital of the University of Pennsylvania
4d 3400 Civic Center Drive, 3 Perelman Center
Philadelphia, PA 19104
26
25 Division of Surgical Oncology
32 Hospital of the University of Pennsylvania
4d 3400 Civic Center Drive, 3 Perelman Center
Philadelphia, PA 19104
30
Office: (215) 662-4392
30
9f
12
30
13
Education:
21 9 B.S. 19 (Biochemistry) c
2c University of Maine, 1982.
21 a Ph.D. c
37 Rutgers University/UMDNJ/RWJMS, 1988.
21 9 M.D. c
6e University of Medicine and Dentistry of New Jersey/Robert Wood Johnson Medical School, 1988.
c
3
3
3
3
90
Permanent link21 9 B.S. 19 (Biochemistry) c
2c University of Maine, 1982.
21 a Ph.D. c
37 Rutgers University/UMDNJ/RWJMS, 1988.
21 9 M.D. c
6e University of Medicine and Dentistry of New Jersey/Robert Wood Johnson Medical School, 1988.
c
2 29
21
1e
1d
24
13
29
27
23
16f Bahl S, Roses R, Sharma, A, Koldovsky U, Xu S, Weinstein S, Nisenbaum H, Fox K, Pasha T, Zhang P, Araujo L, Carver J, Czerniecki BJ.: Asymptomatic changes in cardiac function can occur in DCIS patients following treatment with HER-2/neu pulsed dendritic cell vaccines. Am Journal Surgery. 2009.
15a Roses RE, Paulson C, Sharma A, Schueller JE, Nisenbaum H, Weinstein S, Fox KR, Zhang PJ, Czerniecki BJ.: HER-2/neu over-expression as a predictor for the transition from in situ to invasive breast cancer. Cancer Epidemiology, Biomarkers and Prevention. 18: 1386-1389, 2009.
ec Roses R, Xu M, Koski GK, Czerniecki BJ.: Radiation therapy and toll-like receptor signaling: implications for the treatment of cancer. Oncogene. 27: 200-207, 2008.
10b Sharma A, Czerniecki BJ.: Utilizing Genetic Phenotypes and Cancer Stem Cells as Novel Targets for Breast Cancer Vaccine Development. Current Medical Literature Breast Cancer. 20(3): 61-67, 2008.
17d Kuerer HM, Albarracin CT, Yang WT, Cardiff RD, Brewster AM, Symmans WF, Hylton NM, Middleton LP, Krishnamurthy S, Perkins GH, Barbiera G, Edgerton ME, Czerniecki BJ, Arun BK, Hortobagyi GN.: Ductal carcinoma in situ: state of the science and roadmap to advance the field. J Clinical Oncology. 27: 1-10, 2008.
de Koski GK, Roses R, Xu S, Cohen PA, Czerniecki BJ.: Re-engineering dendritic cell-based anti-cancer vaccines. Immunologic Reviews. 222: 256-276, 2008.
131 Roses RE, Xu S, Xu M, Koldovsky U, Koski G, Czerniecki BJ.: Differential production of interleukin-23 and interleukin-12 by myeloid derived dendritic cells in response to toll-like receptor agonists. J Immunol. 181: 5120-5127, 2008.
18c Tchou J, Greshock J, Bergey M, Sonnad SS, Sargen M, Weinstein S, Czerniecki B, Boraas M, Fraker DL, Rosato E, Fox K, Weber B, Solin LJ.: Method of primary tumor detection as a risk factor for local and distant recurrence after breast conservation treatment for early stage breast cancer. Clinical Breast Cancer. 8: 2, 2008.
18e Cohen PA, Koski GK, Czerniecki BJ, Bunting K, Fu XY, Wang Z, Zhang WJ, Carter C, Awad M, Distel CA, Hassen N, Paustian C, Johnson T, Tisdale JF, Shu S.: STAT3- and STAT5-dependent pathways competitively regulate the pan-differentiation of CD34 positive cells into tumor-competent dendritic cells. Blood. 112: 1832-1843, 2008.
2c
7
1d
1f
Selected Publications
1b9 Choe, R, Konecky SD, Corlu A, Lee K, Durduran T, Busch DR, Pathak S, Czerniecki BJ, Tchou J, Fraker DL, DeMichele A, Chance B, Arridge SR, Schweiger M, Culver JP, Schnall MD, Putt ME, Rosen MA,Yodh AG.: Differentiation of benign and malignant breast tumors by in vivo three dimensional parallel-plate diffuse optical tomography. Journal of Biomedical Optics. 14, 2009.16f Bahl S, Roses R, Sharma, A, Koldovsky U, Xu S, Weinstein S, Nisenbaum H, Fox K, Pasha T, Zhang P, Araujo L, Carver J, Czerniecki BJ.: Asymptomatic changes in cardiac function can occur in DCIS patients following treatment with HER-2/neu pulsed dendritic cell vaccines. Am Journal Surgery. 2009.
15a Roses RE, Paulson C, Sharma A, Schueller JE, Nisenbaum H, Weinstein S, Fox KR, Zhang PJ, Czerniecki BJ.: HER-2/neu over-expression as a predictor for the transition from in situ to invasive breast cancer. Cancer Epidemiology, Biomarkers and Prevention. 18: 1386-1389, 2009.
ec Roses R, Xu M, Koski GK, Czerniecki BJ.: Radiation therapy and toll-like receptor signaling: implications for the treatment of cancer. Oncogene. 27: 200-207, 2008.
10b Sharma A, Czerniecki BJ.: Utilizing Genetic Phenotypes and Cancer Stem Cells as Novel Targets for Breast Cancer Vaccine Development. Current Medical Literature Breast Cancer. 20(3): 61-67, 2008.
17d Kuerer HM, Albarracin CT, Yang WT, Cardiff RD, Brewster AM, Symmans WF, Hylton NM, Middleton LP, Krishnamurthy S, Perkins GH, Barbiera G, Edgerton ME, Czerniecki BJ, Arun BK, Hortobagyi GN.: Ductal carcinoma in situ: state of the science and roadmap to advance the field. J Clinical Oncology. 27: 1-10, 2008.
de Koski GK, Roses R, Xu S, Cohen PA, Czerniecki BJ.: Re-engineering dendritic cell-based anti-cancer vaccines. Immunologic Reviews. 222: 256-276, 2008.
131 Roses RE, Xu S, Xu M, Koldovsky U, Koski G, Czerniecki BJ.: Differential production of interleukin-23 and interleukin-12 by myeloid derived dendritic cells in response to toll-like receptor agonists. J Immunol. 181: 5120-5127, 2008.
18c Tchou J, Greshock J, Bergey M, Sonnad SS, Sargen M, Weinstein S, Czerniecki B, Boraas M, Fraker DL, Rosato E, Fox K, Weber B, Solin LJ.: Method of primary tumor detection as a risk factor for local and distant recurrence after breast conservation treatment for early stage breast cancer. Clinical Breast Cancer. 8: 2, 2008.
18e Cohen PA, Koski GK, Czerniecki BJ, Bunting K, Fu XY, Wang Z, Zhang WJ, Carter C, Awad M, Distel CA, Hassen N, Paustian C, Johnson T, Tisdale JF, Shu S.: STAT3- and STAT5-dependent pathways competitively regulate the pan-differentiation of CD34 positive cells into tumor-competent dendritic cells. Blood. 112: 1832-1843, 2008.
2c